Anti-CD38 Antibody Treating Evans Syndrome
- Conditions
- TreatmentEvan Syndrome
- Interventions
- Drug: Anti-CD38 antibody Injection
- Registration Number
- NCT06014775
- Brief Summary
A single-center, open-label, off-label use investigator-initiated clinical study with safety run-in to explore the clinical activity and safety of Anti-CD38 Antibody in adult ES patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including immunosuppressive agents, Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.
- Detailed Description
Evans' syndrome (ES) is defined as the concomitant or sequential association of warm auto-immune haemolytic anaemia (AIHA) with immune thrombocytopenia (ITP), and less frequently autoimmune neutropenia. ES is a rare situation that represents up to 7% of AIHA and around 2% of ITP. Due to the rarity of the disease, the treatment of ES is mostly extrapolated from what is recommended for isolated auto-immune cytopenia (AIC) and mostly relies on corticosteroids, rituximab, splenectomy, and supportive therapies.Despite continuous progress in the management of AIC and a gradual increase in ES survival, the mortality due to ES remains higher than the ones of isolated AIC, supporting the need for an improvement in ES management.
A branch of pathogenesis for ES has been revealed that plasma cells secrete pathogenic antibodies directed against platelet and red blood cell antigens. Antiplatelet specific plasma cells have been detected in the spleen of patients with rituximab refractory ITP. In those refractory cases, persistent autoreactive long-lived plasma cells in the bone marrow could explain treatment failure.
Anti-CD38 antibody, such as Daratumumab, has been developed to target tumoral plasma cells in multiple myeloma, was recently found to be effective in antibody-mediated diseases, such as autoimmune cytopenia following hematopoietic stem cell transplantation, systemic lupus and also ES.
This study will evaluate the safety and biologic activity of Anti-CD38 antibody in r/r primary ES who fail to respond to at least one previous second-line therapy or those who cannot chose suitable second-line therapy. The study will enroll approximately 10 participants. This trial will be conducted in China. All participants will be followed for at least 16 weeks after the 8 weeks of treatment.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 10
- Male or female aged ≥18 years.
- Prior to enrollment, a clinical diagnosis of primary Evans syndrome was made.
- Platelet count < 30×10^9/L or Hb < 100g/L or symptomatic anemia within 48 hours before the first administration of study drug;
- Failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy or those who cannot chose other second-line therapy;
- If receiving emergency care for ES, treatment should be stopped >2 weeks before first dose.
- DAT positive (IgG+, with or without C3+).
- The patient need to be in the state of active hemolysis.
- With normal hepatic and renal functions.
- ECOG performance status ≤2.
- Cardiac function: New York Heart Association functional class ≤2.
- For patients receiving maintenance treatment, corticosteroids must have a stable dose at least 2 weeks before the first administration, TPO receptor agonists and azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first administration; The end of anti-CD20 antibody treatment was>6 months.The end of alkylating agent treatment was>2 months.
- Understand the study procedures and voluntarily sign the informed consent form in person.
- Secondary Evans syndrome. Received any treatment of anti-CD38 antibody drug
- Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases;
- HIV positive;
- Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive;
- Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc.;
- At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled;
- Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis;
- Those who have received allogeneic stem cell transplantation or organ transplantation in the past;
- Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up;
- Patients whose toxic symptoms caused by pre-trial treatment have not disappeared;
- Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.);
- Patients with septicemia or other irregular severe bleeding;
- Patients taking antiplatelet drugs at the same time;
- Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Intervention（Anti-CD38 antibody） Anti-CD38 antibody Injection 10 enrolled subjects : once a week x 8 doses
- Primary Outcome Measures
Name Time Method Safety of Anti-CD38 antibody treatment 24 weeks Incidence, severity, and relationship of treatment emergent adverse events after Anti-CD38 antibody treatment
Evaluation of overall efficacy response after Anti-CD38 antibody treatment within 8 weeks 8 weeks Overall response rate defined as improvement in any cytopenias by at least one grade, without worsening any other cytopenias or stable disease at least once within 8 weeks after the first dose.
- Secondary Outcome Measures
Name Time Method Measurements of Hb value at each visit time point 24 weeks Hb value at each visit time point
Measurements of hemolytic marker reticulocyte count at each visit time point 24 weeks hemolytic marker reticulocyte count at each visit time point
Emergency treatment 24 weeks Percentage of subjects who received emergency treatment
Duration of Hb response 24 weeks The longest duration for which the subject sustained a Hb level ≥100 g/L, or a Hb level increased more than 20g/L than baseline
Evaluation of stable sustained response after Anti-CD38 antibody treatment at week 8 8 weeks Stable sustained response rate defined as improvement in any cytopenias by at least one grade, without worsening any other cytopenias or stable disease in 3 consecutive accessible assessments at least 7 days apart 8 weeks after the first dose.
Number of Participants With ES Response to Anti-CD38 antibody treatment 24 weeks Complete response (CR) is complete resolution in all autoimmune cytopenias (neutropenia, anemia thrombocytopenia) maintained for more than two months, combined with an ability to wean off corticosteroids and/or other immunosuppressive medication. Partial response (PR) is improvement in any cytopenias by at least one grade, lasting more than two months, without worsening any other cytopenias or stable disease with the ability to wean corticosteroids and/or immunosuppressive medications by at least 50%. No response (NR) is no change in cytopenias with treatment, and the inability to wean corticosteroids or other immunosuppressive medications. Progressive disease (PD) refers to obtaining a CR or PR by the 3 month observation and relapsing or progressing by the 6 month observation, leading to cessation of study drug.
Measurements of hemolytic marker LDH at each visit time point 24 weeks hemolytic marker LDH at each visit time point
Measurements of hemolytic marker haptoglobin at each visit time point 24 weeks hemolytic marker haptoglobin at each visit time point
Duration of platelet response 24 weeks The longest duration for which the subject sustained a platelet count ≥50×109/L and at least 2-fold from baseline at the meanwhile
Measurements of platelet count at each visit time point 24 weeks Platelet count at each visit time point
Measurements of hemolytic marker total bilirubin at each visit time point 24 weeks hemolytic marker total bilirubin at each visit time point
Assessment of fatigue function in chronic disease treatment 24 weeks The scores of Functional Assessment of Fatigue in Chronic Illness Therapy (FACIT-F) before and after Anti-CD38 antibody treatment
Reduction of concomitant drug 8 weeks Percentage of patients with reduced doses of corticosteroids and/or other concomitant immunosuppressive drugs at baseline by 8 weeks of treatment
Number of subjects with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale 24 weeks Changes of the subjects' numbers in WHO bleeding score after Anti-CD38 antibody treatment according to the reported World Health Organization's Bleeding Scale. The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.
Health status survey 24 weeks The change of Health status Questionnaire (SF-36) score before and after Anti-CD38 antibody treatment
Trial Locations
- Locations (1)
Chinese Academy of Medical Science and Blood Disease Hospital
🇨🇳Tianjin, Tianjin, China